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Abstract
BACKGROUND: Electrocardiogram (ECG) signs on admission can serve as a prognostic marker in patients treated 
for myocardial infarction (MI).
AIM: The aim of the study was to determine the predictive role of modified Anderson–Wilkins (MAW) ECG score of 
acuteness on the extent of myocardial injury, left ventricular (LV) remodeling, and clinical outcome in patients with 
acute MI.
METHODS: Prospective, observational cohort study on patients treated for MI at the University Clinic for Cardiology. 
Subjects were analyzed for their demographic, clinical, ECG, LV functional, angiographic variables, course of 
treatment, and in-hospital outcome. MAW score was calculated for each patient. Patients were comparatively 
analyzed divided in two groups (score <3 and ≥3).
RESULTS: One hundred fifty patients (70% males and 30% females), aged 60.9 years were included in the study. 
Sixty-eight patients had MAW score <3 (mean 1.7), and 82 had score ≥3 (mean 3.5), p>0.001. Patients with 
ST-segment elevation MI had OR 2.1 (p>0.000), and patients with multiple locations (excluding anterior) had OR 2.1 
(p > 0.000) of having MAW score ≥3. They received mechanical reperfusion 1.9 (p = 0.032) times more often. High 
MAW score was associated with stress hyperglycemia (OR 2.1; p = 0.032); low potassium (OR 2.8; p = 0.032), lower 
creatinine (p = 0.050), and higher NT-proBNP (OR 2.5; p = 0.050). High MAW score was associated with decreased 
LV function and increased LV dimensions on the follow-up echocardiography (p = 0.050 and 0.012, respectively).
CONCLUSION: ECG is an important prognostic tool in MI patients. ECG-derived MAW score demonstrates a strong 
correlation with stress hyperglycemia, potassium, creatinine, and natriuretic peptides level and can serve as an early 
marker of LV remodeling after MI.
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Introduction
Acute myocardial infarction (AMI) is one of the 
leading causes of death worldwide, with cardiovascular 
diseases (CVD) being responsible for 31.8% of all 
deaths [1]. With a longer duration of myocardial 
ischemia, the size of irreversibly injured and necrotic 
myocardium is increasing, and the extent of myocardial 
salvage is decreasing. Nevertheless, the speed of 
necrosis progression depends on the vulnerability of 
the myocardium to ischemia and demonstrates great 
variations among patients. Myocardial ischemia is related 
to the amount of collateral blood flow of the coronary artery 
and metabolic preconditioning of the myocardium [2], [3]. 
The progression of myocardial ischemia to myocardial 
necrosis translates into myocardial segmental wall motion 
abnormalities estimated by electrocardiography [4].
The rapid revascularization of the acutely occluded 
coronary artery, either with the primary percutaneous 
coronary intervention (pPCI) or thrombolytic therapy, is 
of paramount significance for myocardial salvage, risk of 
subsequent heart failure, and survival [5], [6], [7].
Yet, estimation of symptom onset is very biased 
by sometimes inaccurate patient recollection or pre-
existing conditions leading to clinically “silent” myocardial 
ischemia. Here, we stress again the very important role 
of electrocardiogram (ECG) and ECG signs of acuteness 
and severity of the myocardial injury. The Anderson–
Wilkins acuteness score (AW score) quantifies the 
acuteness of myocardial ischemia from the ECG, and 
according to published literature on this subject, it is 
superior to historical timing and treatment delay (time 
from symptom onset to wire) in predicting myocardial 
infarct size, salvage, and mortality [8], [9], [10].
The Anderson–Wilkins acuteness score 
evaluates the acuteness of myocardial ischemia in 
patients presenting with acute thrombotic occlusion of 
coronary artery, based on a 12-lead standard ECG. [11] 
Briefly, an acuteness phase is assigned based on the 
presence or absence of a hyperacute T-wave or an 
abnormal Q-wave [12]. According to the AW score, 
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there are four phases, starting with the most acute 
one: Phase 1A: Hyperacute T-wave and no abnormal 
Q-wave; phase 1B: Positive T-wave and no abnormal 
Q-wave; phase 2A: Tall T-wave and abnormal Q-wave; 
and phase 2B: Positive T-wave and abnormal Q-wave. 
The AW score ranges from 1 to 4, with 1 being the least 
acute and 4 being most acute. Acute ischemia is defined 
as ECG acute score ≥3 and non-acute ischemia as 
ECG acuteness score <3 [13], [14]. The AW score may 
indicate an electrophysiological estimate of the viability 
of the myocardium, independently of the patient-
reported symptoms onset, and may subsequently 
be used as a predictor of achievable myocardial 
salvage [11], [12], [13].
Echocardiography is the most frequently used 
non-invasive diagnostic technique which provides 
information regarding ventricular function and presence 
or absence of wall motion abnormalities [15]. Left 
ventricular ejection fraction (LVEF) and volumes are 
well-known predictors of prognosis in patients with AMI. 
Lower EF and larger volumes result in worse clinical 
outcomes [16]. According to authors White et al. [17] 
and Møller et al. [18], post-MI patients with EF <40% 
and end-systolic volume >130 cm3 have a 5-year 
survival rate of 65% and 52%, respectively.
In this study, we aimed to determine if there 
is a place for modified Anderson–Wilkins (MAW) ECG 
score of acuteness in the prediction of the extent of 
myocardial injury, as measured with biochemical and 
echocardiography-gained parameters. Our secondary 
goal was to find out if this score can serve as a predictor 
of early in-hospital outcome in MI patients.
 Methods
A longitudinal, prospective observational 
cohort study was undertaken on patients hospitalized 
at the University Clinic of Cardiology over the period of 
September 2018–March 2019 for acute MI. Inclusion 
criteria: Patients (all incomers) hospitalized for AMI over 
the aforementioned period who were willing to participate 
in the study and gave signed informed consent. 
Exclusion criteria: Patients who were not consented 
to participate in the study and patients who suffered 
in-hospital mortality over the index hospitalization.
Data were collected on demographics, CV 
risk factors, comorbidities, ECG-signs of myocardial 
injury, biomarkers of myocardial injury, LV function, 
angiographic distribution of the disease, MI treatment, 
and medications used and early in-hospital outcome.
At the study entry, to collect variables of interest, 
every patient underwent: taking medical history; physical 
examination; 12-lead ECG recording; blood sampling 
for: Hemogram, lipid (non-fasting), and glycemic profile, 
markers of myocardial injury: Highly sensitive troponin 
T/I (hsTn) and brain natriuretic peptide (NTpro-BNP), 
biochemical parameters; coronary angiography and 
echocardiography (2-D transthoracic echocardiography 
[2D TTE]).
The first post-hospital evaluation was 
performed in the time-frame period of 3–6 months after 
the index event. Medical history, physical examination, 
12-lead ECG, and 2D TTE were undertaken.
Stratification of patients according to the 
severity and acuteness of ischemia was made from 
the admission electrocardiogram (12-lead pre-hospital 
or first in-hospital ECG recording with good quality 25 
mm/s, 10 mm/mV, and 150 Hz). For the purposes of 
our study, we applied the calculation of the modified 
Anderson–Wilkins (MAW) ECG score of acuteness, in 
details described by Hedén et al. [13], according to the 
following formula:
4(#leads 1A) + 3(#leads 1B)
+2(#leads 2A) +1(#leads 2B)Accuteness score =
#leads with 1A, 1B, 2A, 2B∑
Patients were divided in two groups: Group A: 
MAW ECG score of acuteness = 0 (<3) and Group B: 
MAW ECG score of acuteness = 1 (≥3).
The study was approved by the ethics 
committee of the University Clinic of Cardiology and was 
conducted in accordance with the Helsinki Declaration. 
Informed consent was obtained from all patients before 
their inclusion in the study.
IBM SPSS statistical software version 22 was 
used for statistical analysis. Descriptive and comparative 
statistical methods were applied. Continuous variables 
were presented as means, while categorical as 
frequencies and percentages.  Comparative statistic 
tests: Chi-square test for variables with dichotomous 
distribution, t-test, and one-way ANOVA for continuous 
variables with two or more categories were applied. Risk 
ratios with a 95% confidence interval were calculated, 
and the significance was determined using Cochran and 
Mantel-Haenszel test. Receiver operating characteristic 
(ROC) curves (receiver operator characteristic curves) 
were used for prediction capability. Correlations, uni- and 
multivariate linear, and logistic regression analysis were 
undertaken to identify significantly associated variables. 
Significance was determined at the level of 0.05.
 Results
Patients treated for AMI at the University Clinic 
of Cardiology over the period of September 2018-March 
2019, were 150 in total, with 70% males and 30% females, 
at mean age of 61 years were subjected to analysis.
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No statistically significant differences were 
observed in age and gender distribution (Figure  1) and 
CV risk profile, except for hyperlipidemia and arterial 
hypertension being more frequent in patients with 
MAW score <3 (OR 1.5 and 1.6, p=0.038 and p=ns, 
respectively) (Table 1).
SC 148 (98.7%) 2 (1.3%) 0 ns
Aces site
Radial 144 (97.3%) 65 (98.2%) 74 (96.3%) ns
other 4 (2.7%) 1 (1.8%) 3 (3.7%)
NO of diseased 
vessels
1.9 ± 0.9 1.8 ± 1.0 1.9 ± 0.8 ns
SINTAX score 15.3 ± 7.1 14.9 ± 8.6 15.6 ± 5.7 ns
NO of treated vessels 0.9 ± 0.3 0.9 ± 0.4 1.1 ± 0.2 0.003
Type of treatment
PCI (including 
POBA and 
thromboaspiration)
137 (91.3%) 55 (80.9%) 82 (100%) 1.9 (1.1–3.2)
Medical treatment 9 (6%) 9 (13.2%) 0 0.000 0.032
Urgent CABG 4 (2.7%) 4 (5.9%) 0
Reperfusion
NO 5 (7.4%) 1 (1.2%) 6 (4%) 0.067
YES 63 (92.6%) 81 (98.8%) 144 (96%)
Medical treatment
ASA 146 (97.3%) 64 (94.1%) 82 (100%) 0.040
P2Y12 148 (98.7%) 66 (97.1%) 82 (100%) ns
BB 90 (60%) 37 (54.4%) 53 (64.6%) ns
RAAS 131 (87.3%) 58 (85.3%) 73 (89%) ns
MRA 36 (24%) 12 (17.6%) 24 (29.3%) 0.070 1.5  
(0.9-2.5); ns
Loop diuretics 60 (40%) 22 (32.4%) 38 (46.3%) 0.057 1.4  
(0.9-2.1); ns
DM treatment 31 (20.7%) 13 (19.1%) 18 (22%) ns
Hospitalization 5.2±2.3 5.1±2.4 5.4±2.2 ns
In-hospital morbidity 31 (20.7%) 13 (19.1%) 18 (22%) ns 1.1  
(.7-1.7); ns
In-hospital mortality 4 (2.7%) 2 (2.9%) 2 (2.4) ns
ASA: Acetylsalicylic acid, BB: Beta-blockers, BMI: Body mass index, BSA: Body surface area, COPD: 
Chronic obstructive pulmonary disease, CABG: Coronary artery bypass grafting, DM: Diabetes mellitus, 
EF: Ejection fraction, GIT: Gastrointestinal tract, HLP: Hyperlipidemia, HTA: Hypertension, MI: Myocardial 
infarction, PCI: Percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infarction, 
NSTEMI: Non-ST-segment elevation myocardial infarction, SC: Selective coronarography, NO: Number, 
SINTAX score: Synergy between PCI with Taxus and cardiac surgery score, PCI: Percutaneous coronary 
intervention, POBA: Plain old balloon angioplasty, P2Y12: Antiplatelet drug – P2Y12 inhibitors, RAAS: Renin-
angiotensin-aldosterone system blockers, MRA: Aldosterone receptor antagonists.
From 150 MI patients, 71.3% had STEMI 
and an OR of 2.1 (p > 0.000), having MWA score ≥3. 
A statistically significant difference for MAW score was 
observed in patients according to the MI location. In 
patients with anterior MIs, there was an equal distribution 
of MAW score, while MAW score < 3 predominated in 
patients with inferior MIs, and score ≥3 predominated in 
patients with multiple locations excluding anterior MI, OR 
2.1 (p = 0.016). Furthermore, Group B patients had bigger 
ST-segment elevation (p > 0.000), while no difference was 
observed with respect to the transmural distribution of MI 
(as expressed through the presence of Q sequela). No 
significant differences in the MAW score were observed 
with respect to the extent and severity of the disease, as 
assessed angiographically (Table 1).
Figure 1: Population plot – distribution of MAW score across genders, 
with horizontal reference line set at value of 3
Table 1: Clinical characteristics of the study group and in the 
two comparator groups
Variable Total
(No./%)
Group A
(Score <3)%
Group B
(Score ≥3)%
Sig. OR (for 
categorical 
variables)  
(95% CI)
Gender 150 (100) 68 (45.3) 82 (54.7)
nsFemale 45 (30) 20 (44.4) 25 (55.6)
Male 105 (70) 48 (45.7) 57 (54.3)
Age (years) 60.9 ± 11.9 60.8 ± 11.9 61.0 ± 12.0 ns
BMI (kg/m) 28.4 ± 4.9 28.8 ± 4.1 28.2 ± 5.3 ns
BSA (kg/1m2) 1.9 ± 0.2 1.9±0.1 1.9±0.2 ns
Obesity (BMI >30) 20 (13.3) 6 (8.8) 14 (17.1) ns
HLP 137 (91.3) 66 (97.4) 71 (86.6) 0.021* 1.6 (1.2–2.2); 
0.038
Family history 87 (58) 40 (58.8) 47 (57.3) ns
Smoking 98 (65.2) 42 (61.8) 56 (68.3) ns
HTA 133 (88.7) 64 (94.1) 69 (84.1) 0.046* 1.5 (1.0–2.0); ns
DM 44 (29.3) 19 (27.9) 25 (30.5) ns
Previous MI 21 (14) 11 (16.2) 10 (12.2) ns
Previous PCI 20 (13.3) 10 (14.7) 10 (12.2) ns
Preexisting EF <50% 8 (5.3) 4 (5.9) 4 (4.9) ns
COPD 18 (5.3) 6 (8.8) 12 (14.6) ns
Anemia 11 (7.3) 6 (8.8) 5 (6.1) ns
GIT disease 10 (6.7) 5 (7.4) 5 (6.1) ns
EF: Ejection fraction, PCI: Percutaneous coronary intervention, BMI: Body mass index, BSA: Body surface 
area, HLP: Hyperlipidemia, HTA: Hypertension, MI: Myocardial infarction, COPD: Chronic obstructive 
pulmonary disease, DM: Diabetes mellitus, GIT: Gastrointestinal tract.
However, there were significant differences 
in MAW score and therapeutic treatment approach. 
Patients with MAW score ≥3 had OR of 1.9 (p = 0.033) 
for receiving primary PCI (pPCI) treatment as compared 
to patients from Group A. Furthermore, patients from 
Group B more frequently received revascularization on 
more than one “culprit” coronary artery (p=0.003). As 
for medical therapy, patients from Group B had OR of 
1.5 and 1.4 (p = ns for both) to receive mineralocorticoid 
receptor antagonists and loop diuretics. No significant 
differences for in-hospital morbidity or mortality were 
observed, although they were statistically insignificantly 
higher in Group B patients (Table 1).
Surprisingly, no significant differences were 
found for LV function between the groups, not only on the 
first in-hospital echocardiography but also on the 3–6-
month follow-up test (after the period of LV remodeling). 
In the patients from Group B, statistically significant 
thinner IVS was observed (0.009), which can be 
discussed accompanied with Q-wave sign of transmural 
MI that was more frequent in the same patients (Table 2).
Table 2: LV morphologic and functional variables as measured 
by 2-D TTE of the study group and in the two comparator 
groups on the first and second study
Variable Total
(No./%)
Group A
(Score <3)%
Group B
(Score ≥3)%
Sig.
First measurement
LVEDd (mm) 51.8 ± 5.1 52.1 ± 5.2 51.6 ± 5.0 ns
LVESd (mm) 36.5 ± 5.7 36.5 ± 5.7 36.5 ± 5.7 ns
EF (%) 52.4 ± 9.6 52.7 ± 9.1 52.2 ± 10.1 ns
LA (mm) 38.2 ± 4.4 38.6 ± 3.8 37.8 ± 4.8 ns
IVS (mm) 11.5 ± 1.7 11.9 ± 1.6 11.2 ± 1.8 0.009
Diastolic dysfunction 59 (40.4) 26 (39.4) 33 (41.3) ns
LV dysfunction
EF <50% 70 (46.7) 32 (47.8) 38 (47.5) ns
EF >50% 77 (51.3) 35 (52.2) 42 (52.5)
Second measurement
LVEDd (mm) 53.5 ± 5.1 53.1 ± 5.6 53.7 ± 4.9 ns
LVESd (mm) 38.4 ± 5.2 37.9 ± 5.2 38.7 ± 5.3 ns
EF (%) 50.6 ± 8.4 51.5 ± 7.7 50.1 ± 8.9 ns
LA (mm) 39.3 ± 3.9 39.6 ± 4.0 39.2 ± 3.9 ns
IVS (mm) 11.0 ± 2.2 10.9 ± 2.6 11.1 ± 2.0 ns
Diastolic dysfunction 29 (70.7) 11 (78.6) 18 (66.7) ns
LV dysfunction
EF <50% 24 (37.5) 9 (37.5) 15 (37.5) ns
EF >50% 77 (62.5) 15 (62.5) 25 (62.5)
2-D TTE: 2-dimensional transthoracic echocardiography, LVEDd: Left ventricular end-diastolic dimension, 
LVEDs: Left ventricular end-systolic dimension, EF: Ejection fraction, LA: Left atrium; IVS: Interventricular 
septum
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We performed a paired samples analysis for 
each patient on the first and second echocardiography 
study, and also after dividing the patients according to their 
MAW score (Table 3). We found no statistically significant 
difference in EF; however, a significant increase in LV 
dimensions was observed (p = 0.002 and p = 0.013, 
respectively). A comparative analysis between groups 
demonstrated that even in the absence of difference in 
mean EF on the first study, on the second study, patients 
from Group B had statistically significant lower EF. We 
found no significant differences in LVED dimension; 
however, LVES dimension was significantly higher on 
the first and on the second 2 TTE study in patients from 
Group B ( p = 0.012 and 0.050, respectively).
Table 3: Left-ventricular parameters of the study group and in 
the two comparator groups
Variable Total Group A
(Score <3)
Group B
(Score ≥3)
Sig (2-tailed) 
between groups
EF(%) first 51.9 ± 8.7 53.4 ± 6.3 50.9 ± 9.8 ns
EF(%) second 50.6 ± 8.4 51.5 ± 7.7 50.1 ± 8.9 0.051
Sig. f vs. s ns 0.049 ns
LVEDd (mm) first 51.4 ± 5.2 50.8 ± 5.5 51.8 ± 5.0 ns
LVEDd (mm) second 53.5 ± 5.1 53.1 ± 5.6 53.7 ± 4.9 ns
Sig. f versus s 0.002 0.024 0.033
LVEDs (mm) first 36.7 ± 4.7 36.2 ± 5.0 37.2 ± 4.5 0.012
LVEDs (mm) second 38.4 ± 5.2 37.9 ± 5.2 38.6 ± 5.3 0.050
Sig. f versus s 0.013 ns ns
EFf-EF: From the first study; EFs-EF: From the second study, LVEDdf-LVEDd: From the first study, LVEDds-
LVEDd: From the second study, LVESdf-LVESd: From the first study, LVESds-LVESd: From the second 
study.
Out of all analyzed biochemical variables, 
stress glycemia was significantly higher in Group B 
patients (p = 0.011), who also demonstrated worse 
glycemic control over the course of hospital treatment, 
with observed episodes of Gl >10 mmol/L (OR 1.6, 
p = ns). Potassium level was found to be lower in Group 
B (p = 0.012), while creatinine level was higher in Group 
A patients (p = 0.050). Interestingly, patients from Group 
B had 2.6 times higher relative risk of elevated NTpro-
BNP levels (p = 0.060) (Table 4).
Variables that we found to be significantly 
associated with the MWA score were subjected to 
univariate binary logistic regression analysis to confirm 
significant associations. Hyperlipidemia and arterial 
hypertension were found to be negatively associated 
with MWA score 1, as were low serum potassium and 
creatinine levels. STEMI patients had 5.6 times higher 
risk to have MWA score >3 and MIs with multiple 
locations, as compared to anterior MIs (OR 2.3), while 
the lowest OR was found for inferior MIs (OR 0.2). 
Positive association with MWA score ≥3 (Group B) was 
found for number of treated vessels. Stress glycemia 
was higher in Group B patients, who had 2.3 times 
higher risk of having unsatisfactory glycemic control. 
Borderline significance was detected for IVS thickness 
and the use of diuretics over the hospital course of 
treatment (Table 5).
We identified seven independently associated 
identifiers with a high MAW score using multivariate 
logistic regression analysis (backward conditional) 
and a model with a Chi-square test (test statistic 
50.856; p = 0.000; percent correct prediction 74.1%). 
The identifiers were: STEMI, STEMI with multiple 
locations (excluding anterior), presence of stress 
hyperglycemia, creatinine and potassium, thin IVS, and 
treatment with diuretics during a hospital stay (Table 6).
We also analyzed correlations between MAW 
score and various disease variables and significant 
correlation coefficients are displayed in Table 7 and 
Figure 2.
Predictive functions of various biochemical 
variables (hsTn, NTpro-BNP, stress glycemia, WBC, 
creatinine, and potassium) were subjected to ROC curve 
analysis (Figure 3 with accompanying table). Only two 
biochemical variables demonstrated statistically significant 
discriminatory function for MWA score (≥3): High-stress 
glycemia and low serum potassium (area under the curve 
.618, and .371, p=0.013 and 0.007, respectively).
Table 4: Biochemical variables of the study group, and in the two comparator groups
Variable Total (No./%) Group A (Score <3)% Group B (Score ≥3)% Sig. OR (95% CI)
Hemogram
Er (×109) 4.7 ± 0.6 4.7±0.6 4.8±0.6 ns
Hgb (g/L) 141.1 ± 17.8 140.4 ± 18.7 141.7 ± 17.1 ns
Hct (%) 41.4 ± 4.5 41.3 ±4.8 41.4 ± 4.4 ns
Le (×109) 11.3 ± 3.5 10.9 ± 3.5 11.6 ± 3.6 ns
PLT (×106) 247.1 ± 70.3 256.7 ± 85.2 239.1 ± 54.3 ns
Glycemic status
Stress glycemia (mmol/L) 9.4±4.6 8.3±3.7 10.2±5.1 0.011
Stress hyperglycemia 92 (61.7) 35 (52.2) 57 (69.5) 0.023 2.1 (1.1–4.1) p=0.032
HbA1c (%) 6.3 ± 1.5 6.3 ± 1.4 6.3 ± 1.5 ns
Glico regulation
>4–<10 mmol/L 112 (74.7) 54 (79.4) 58 (70.7) ns 1.6 (0.7-3.4)
>10 mmol/L 38 (25.4) 14 (20.6) 24 (29.3)
Lipoproteins
Cholesterol (mmol/L) 5.7 ± 1.3 5.6 ± 1.3 5.9 ± 1.2 ns
LDL-C (mmol/L) 3.5 ± 1.1 3.4 ± 1.2 3.6 ± 1.1 ns
HDL-C (mmol/L) 1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3 ns
TG (mmol/L) 2.0 ± 1.6 1.9 ± 1.4 2.1 ± 1.8 ns
Biochemical variables
BUN (mmol/L) 6.4 ± 3.2 6.7 ± 3.1 6.1 ± 3.3 ns
Creatinine (µmol/L) 87.3 ± 26.6 91.7 ± 27.7 83.6 ± 25.3 0.050
Sodium (mmol/L) 138.3 ± 3.4 138.1 ± 3.5 138.6 ± 3.3 ns
Potassium (mmol/L) 4.2 ± 0.5 4.3 ± 0.6 4.1 ± 0.5 0.012
Potassium <3.5 mmol/L 27 (18.1) 7 (10.4) 20 (24.4%) 0.012 2.8 (1.1–7.0); p=0.032
Cardiac biomarkers
hsTn (ng/L) 9737.5 ± 32148.5 11181.2 ± 40916.2 8525.5 ± 22509.6 ns
NTpro-BNP (pg/ml) 3171.8 ± 5378.7 2875.2 ± 5230.5 3417.8 ± 5504.0 ns
NTpro-BNP >125 pg/ml 130 (86.7) 55 (80.9) 75 (91.5) 0.049 2.5 (0.9–6.7); p=0.050
Er: Erythrocytes, Hgb: Hemoglobin, Hct: Hematocrit, Le: Leukocytes, PLT: Platelets, HbA1c: Glycated hemoglobin, LDL-C: Low-density lipoproteins, HDL: High-density lipoproteins, TG: Triglycerides, BUN: Blood urea 
nitrogen, hsTn: High sensitive troponin, NTpro-BNP: N-terminal prohormone of brain natriuretic peptide.
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Table 7: Significant correlations with MAW score
Variable Correlation (r) Sig (p)
Length of hospitalization 0.157 0.056
HLP −0.178 0.029
HTA −0.201 0.014
Type of MI (STEMI) −0.413** 0.000
ST-seg. elevation 0.423** 0.000
NO of treated CA 0.276** 0.000
Stress glycemia 0.169 0.039
WBC 0.166 0.042
Potassium (low) −0.206 0.012
IVS (thin) −0.305** 0.000
HLP: Hyperlipidemia, HTA: Hypertension, MI: Myocardial infarction, NO: Number, CA: Coronary artery, 
WBC: White blood, MAW: Modified Anderson–Wilkins
Test result variable(s) Area Std. Error Asymptotic 
Sig
Asymptotic 95% CI
Lower bound Upper bound
hsTn (ng/L) 0.474 0.048 0.583 0.380 0.567
NTpro-BNP (pg/ml) 0.561 0.048 0.203 0.467 0.654
Stress Gl (mmol/L) 0.618 0.046 0.013* 0.528 0.709
WBC (×109) 0.567 0.047 0.160 0.474 0.660
Creatinine (µmole/L) 0.410 0.047 0.060 0.318 0.503
Potassium (mmol/L) 0.371 0.046 0.007* 0.281 0.460
hsTn: High-sensitive troponin, NTpro-BNP: N-terminal prohormone of brain natriuretic peptide, WBC: White 
blood cells.
According to the first study addressing the 
prognostic value of the MAW acuteness score, 
when stratifying patients by MAW acuteness score, 
the initial difference in myocardial salvage results 
in a long-term difference in mortality, while the 
incidence of re-infarction is independent of the MAW 
score [10].
Table 8: Lead specific criteria for abnormal Q-waves and tall 
T-waves
Lead Abnormal Q-wave Tall T-wave
I ≥30 ms ≥0.50 mV
II ≥30 ms ≥0.50 mV
III ≥30 ms and abnormal Q in aVF ≥0.25 mV
aVR - -
aVL ≥30 ms ≥0.25 mV
aVF ≥30 ms ≥0.50 mV
V1 Any Q-wave ≥0.50 mV
V2 Any Q-wave ≥1.0 mV
V3 Any Q-wave ≥1.0 mV
V4 ≥30 ms ≥1.0 mV
V5 ≥30 ms ≥0.75 mV
V6 ≥30 ms ≥0.50 mV
Ms: Milliseconds, mV: Millivolts.
Association of common comorbidities and 
risk factors for AMI and MAW score
Our data showed that hyperlipidemia and 
arterial hypertension were more frequent in patients 
with MAW score <3 (less acute and less severe).
Arterial hypertension is a well-known major 
risk factor for CAD and MI [20]. Over 90% of MI victims 
bear many risk factors for coronary atherosclerosis 
besides HTN, smoking habit, obesity, dyslipidemia, 
etc. HTN is an independent risk factor over other risk 
factors that may coexist. There is a linear increase in 
the risk of MI with an increase of blood pressure. HTN 
particularly raises the risk of MI in people under 65 
years [21]. Along with HTA, the other major risk factor for 
CVD is hyperlipidemia or dyslipidemia [22], [23], [24], 
[25]. According to Ballarino et al., age, gender, 
receiving therapy for CVD, smoking, hypertension, 
hypercholesterolemia, and increased BMI are all 
predictive of the acute coronary syndrome [26]. In 
the FAST MI registry, patients with Q wave tend to be 
younger, males, with a history of smoking and family 
Discussion
We investigated the predictive value of the MAW 
score of acuteness as compared with biochemical, LV 
functional parameters, extent and severity of CAD, and 
in-hospital clinical outcome. Our general finding is a high 
degree of agreement between MAW score and biochemical 
variables, as measured in the acute phase of MI.
Table 5: Variables associated with MWA score in univariate 
analysis
Variable beta ExpB (95% CI) / Mantel–
Haenszel OR
Sig.
HLP −0.178 1.121 (1.020–1.232) p=0.038 0.021
HTA −0.179 1.118 (1.001–1.250) p=0.065 0.046
STEMI 1.736 5.676 (1.448–22.247) p=0.013 0.000
ST-seg elevation 0.404 0.000
MI location
Multiple versus anterior 0.834 2.303 (0.957–5.544) p=0.063 0.019
Inferior versus anterior −1.367 0.255 (0.098–0.661) p=0.005
NO of treated vessels 0.283 0.000
NTpro-BNP >125pg/ml 0.929 OR 2.532 (0.961–6.765) p=0.064 0.080
Stress hyperglycemia (mmol/L) .158 0.054
Glico-regulation 0.777 2.174 (1.087–4.348) p=0.028 0.026
WBC (×106) 0.147 0.063
Creatinine (µmol/L) 0.165 0.043
Potassium (mmol/L) −0.209 0.010
IVS (mm) −0.271 0.001
Diuretics treatment 0.591 1.806 (0.926–3.523) p=0.083 0.070
HLP: Hyperlipidemia, HTA: Hypertension, STEMI: ST-segment elevation myocardial infarction,  
MI: Myocardial infarction, NO: Number, NTpro-BNP: N-terminal prohormone of brain natriuretic peptide, 
WBC: White blood cells, IVS: Interventricular septum.
Electrocardiography (ECG), since its invention, 
is the main diagnostic tool for MI diagnosis, in the same 
time localizing the site of infarction, with different leads 
representing the specific myocardial areas [19]. The 
evolution of MI begins early after an acute coronary artery 
occlusion and the subsequent ECG changes are caused 
by the development of ischemia and later on necrosis. Initial 
ECG changes - tall T-waves are very often undetected, as 
they develop within minutes after acute occlusion. They 
are followed by the evolvement of ST-segment elevation, 
abnormal Q waves, T-wave inversion, and lastly, resolution 
of the ST-segment elevation [14].
Table 6: Multivariate logistic regression analysis
Variables B Wald Sig. Exp(B) 95% CI for EXP(B)
Lower Upper
STEMI/NSTEMI −1.194 4.514 0.034* 0.303 0.101 0.912
MI location  
(multiple versus)
4.906 0.086
MI anterior −0.987 2.821 0.093 0.373 0.118 1.179
MI inferior −1.305 4.733 0.030* 0.271 0.084 0.879
Number of treated CA 1.316 2.526 0.112 3.727 0.736 18.882
Stress hyperglycemia 
(mmol/L)
0.111 4.131 0.042* 1.118 1.004 1.245
Creatinine (µmol/L) −0.017 3.905 0.048* 0.983 0.966 1.000
Potassium (mmol/L) −1.357 6.076 0.014* 0.257 0.087 0.757
IVS (mm) −0.308 5.423 0.020* 0.735 0.567 0.952
Diuretics treatment 1.212 6.093 0.014* 3.360 1.283 8.798
Constant 11.735 12.305 0.000 124844.073
STEMI: ST-segment elevation myocardial infarction, NSTEMI: Non-ST-segment elevation myocardial 
infarction, MI: Myocardial infarction, IVS: Interventricular septum.
The original Anderson–Wilkins acuteness score 
was developed for MI with anterior localization and could 
not be used when inferior MI was present [12]. The problem 
is the abnormal Q-wave criterion (≥30 ms duration), that 
is rarely met in the inferior leads, where predominantly 
positive QRS complex is expected [13]. The MAW score 
loosens up the strict criteria and adjusts the Q-wave 
criterion from ≥30 ms to ≥20 ms in inferior leads, and thus 
the MAW score predicts myocardial salvage equally well 
for anterior and inferior AMI [8], [13], (Table 8).
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history. Patients with non-Q wave MIs were heavily 
burdened with risk factors and had worse baseline 
demographic characteristics [37].
This might be the explanation why in our study 
population, patients with lower acuteness severity 
index were more often patients with hypertension and 
hyperlipidemia. 
Figure  3:  Receiver  operating  characteristic  curve  for  modified 
Anderson–Wilkins score and biochemical variables
Association of biochemical variables with 
MAW
We found that stress hyperglycemia, serum 
levels of potassium, and creatinine are statistically 
significant associated with the MAW score of acuteness, 
as well as natriuretic peptide (NT-proBNP).
According to the definition of The American 
Diabetes Association, stress hyperglycemia is 
an elevation of fasting glucose ≥7 mmol/L, or 2-h 
postprandial glucose ≥11 mmol/L, in a patient 
without previous diabetes mellitus. Distinction on 
whether a patient has stress glycemia or previously 
undiagnosed diabetes is made by glycated hemoglobin 
(HbA1c). HbA1c value ≥ 6.5% indicates preexisting 
unrecognized diabetes, while value ≤6.5% indicates 
stress hyperglycemia [27]. Studies show that stress 
hyperglycemia is present in one of four hospitalized 
ACS patients, and it is found in 41% of elderly patients. 
Stress hyperglycemia can be used as a prognostic 
indicator in patients with AMI [28], [29] According to 
Marfella et al. [30], patients with hyperglycemia had 
a larger infarct size compared with normoglycemic 
patients, and also, there is evidence that supports 
an association between ventricular desynchrony 
and blood glucose levels in patients with MI, and an 
association with early in-hospital mortality in patients 
with AMI [31].
Our data is in concordance with such findings. 
In our study, patients from Group B had OR of 2.1 
(p = 0.023) of having stress hyperglycemia, which also 
demonstrated a very good discriminatory function as a 
continuous variable with ROC analysis (area under the 
curve .618, p = 0.013).
Normal serum potassium level ranges from 3.5 
to 5.1 mmol/L in adults [32], while low potassium level is 
described in approximately 8% of patients with MI [33]. 
According to Goyal et al., a higher mortality rate can be 
observed in AMI patients with potassium levels below 
3.5 and above 4.5 mmol/L. The “so-called” safe window 
is levels 3.5–4.5 mmol/L [34].
In our study, we found that serum potassium 
was statistically significantly lower in Group B 
(p = 0.012), with an OR of 2.8 (p = 0.032), as compared 
to Group A, to have serum potassium <3.5 mmol/L. No 
significant association with in-hospital morbidity was 
observed.
Renal dysfunction is a strong independent 
predictor of cardiovascular outcome after MI [35]. Cakar 
et al. found that the presence of elevated creatinine 
on admission in STEMI patients is associated with 
increased 1-year mortality, independent of other 
conventional risk factors [36].
We found that patients from Group A had 
higher serum creatinine level (p = 0.048), which is in 
accordance with the literature, as patients with renal 
dysfunction tend more often to be late presenters.
Figure 2: Correlation coefficient matrix of modified Anderson–Wilkins 
score with potassium and stress glycemia
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Natriuretic peptides are not only biomarkers for 
the diagnosis of heart failure but even more important 
prognostic markers. In MI patients, natriuretic peptides 
correlate with the presence and degree of heart 
failure in the early phase, but also, they are powerful 
prognosticators of LV remodeling, LV dysfunction, and 
early and late cardiac morbidity and mortality. Fakhri 
et al. demonstrated the association of MAW score with 
increasing NT-proBNP levels. In STEMI patients with 
severe ischemia, neurohormonal activation is inversely 
associated with ECG patterns of acute myocardial 
ischemia [38]. 
We found high levels of natriuretic peptides 
(NT-proBNP was measured), without inter-group 
statistically significant difference. However, patients 
from Group B had OR 2.5 (p = 0.050), to have 
NT-proBNP level above 125 pg/ml.
LV functional parameters and MAW score
LVEF is one of the well-known predictors of 
prognosis in patients with AMI, the lower the EF, the 
worse the mortality and morbidity will be [16]. The SAVE 
echocardiography substudy reported that larger infarct 
size correlates with LV shape distortion and predicts 
progressive LV dilatation, LV dysfunction, and cardiac 
death [16], [18].
Simple comparative statistics of LV 
morphological and functional parameters measured 
with 2-D TTE on the first and second measurements 
found no statistically significant differences between the 
two groups. However, paired sample statistics revealed 
a completely different situation when comparing LV 
morphology after the 3 months period. This is a period of 
LV remodeling after MI, and we observed that there was 
no significant change in global LV function as measured 
through EF (%). However, signs of LV remodeling can 
be observed through statistically significant increases 
of LV dimensions (end-diastolic and end-systolic, p = 
0.002 and p = 0.013, respectively) that were taken as 
surrogate markers for LV volumes. That said, comparing 
the process of LV remodeling in the patients from the 
two groups, we observed a statistically significant 
decrease of EF on the follow-up study in Group B 
patients, while patients from both groups had increased 
LVES dimensions. It is our conclusion that, even in 
such a small study population, a more pronounced LV 
remodeling can be predicted with a more severe MAW 
score of acuteness.
Fakhri et al. used global longitudinal strain 
analysis (GLS) and reported that pre-hospital risk 
stratification by ECG identifies patients with acute and 
severe ischemia who are at increased risk for reduced 
ventricular function (assessed by GLS) after STEMI. 
Optimizing reperfusion delays in these patients can, 
therefore, be of particular benefit in improving clinical 
outcome after STEMI [4]. 
Limitations
One of the biggest limitations of this study 
is the number of study subjects, bearing in mind the 
prevalence of the disease, which may, in some way, 
affect the results that we received.
Furthermore, another limitation of the study is 
that we only applied 2-D TTE early and after 3 months 
of MI, no imaging modality that can distinct myocardium 
at risk and final area of necrosis was applied.
However, this is the first study done with an 
analysis of NTpro-BNP in a cohort of patients with 
acute MI for prognostication purposes. Even though 
this is a biomarker known for several years, it was not 
widely available in our country, and to our knowledge, 
this is the first study that analyzes the role of natriuretic 
peptides in the prognostication of MI patients.
Conclusion
ECG is still an irreplaceable tool in diagnosis 
and prognosis of MI patients. ECG-derived scores, as 
MAW score, are better surrogate markers of “times” in MI 
patients. MAW score demonstrates a strong correlation 
with biochemical variables: Stress hyperglycemia, serum 
potassium and creatinine level, and natriuretic peptides. 
MAW score can serve as an early marker of LV remodeling, 
as demonstrated by the correlation with LV parameters.
However, we were unable to demonstrate a 
significant association of MAW score with in-hospital 
morbidity nor mortality. Larger scale studies are needed 
to draw such conclusions.
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